At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,328 enrolled
Drug / intervention
Mirikizumab SC +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
In Brief
A Phase 3 clinical trial evaluating Mirikizumab SC, Mirikizumab IV, and 1 other intervention for Ulcerative Colitis. Completed, enrolled 1,328 participants across 385 sites in 34 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesArgentina, Australia, Austria, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartOct 2018
Primary CompletionNov 2021
Study CompletionFeb 2025
TodayJul 2026
First PostedMay 14, 2018
Enrollment StartOct 19, 2018
Primary CompletionNov 3, 2021
Study CompletionFeb 17, 2025
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.1 years ago
Interventions
Mirikizumab SCdrug
Administered SC
Mirikizumab IVdrug
Administered IV
Placebo SCdrug
Administered SC